Exploiting Borders: The Political Economy of Local Backlash against Undocumented Immigrants

Four years prior to Arizona\u27s passage of one of the most far-reaching pieces of anti-Latino immigrant legislation signed into law in decades,3 demands to seal off the border 4 were being made thousands of miles from the U.S.-Mexico divide. In 2006, Hazleton, Pennsylvania, passed equally harsh legislation aimed at keeping undocumented immigrants out of their community. During this time, commentators described the local backlash in Hazleton and other small cities across the United States as akin to the opening of a deep and profound fissure in the American landscape 5 wherein all immigration politics is local. 6 Yet, as the so-called immigration problem returns to its point of origin and the actual U.S.-Mexico border reclaims its place as the popular political referent from the more imaginary yet equally racialized borders of homogeneous interior cities, it appears that neither the Arizona law nor previous local-level legislation represent a new trend but rather an intensification of America\u27s growing anti-Latino immigrant backlash

Block Copolymer Directed Metamaterials and Metasurfaces for Novel Optical Devices

Optical metamaterials are artificially engineered architectures that exhibit desired optical properties not found in nature. Bespoke design requires the ability to define shape, size, orientation, and composition of material structures on the nanometer length scale. Bottom-up self-assembly methods, such as block copolymer (BCP) templating, offer unique pathways to tailored features, at spatial resolution not routinely achieved by conventional top-down techniques. In this review, the authors provide the general readership with basic concepts of the underlying fabrication processes and examine optical phenomena arising from BCP-derived metamaterials and nanoresonators, with both dielectric and plasmonic characteristics. A number of diverse structural conformations designed by BCP templating and their implementation in optical devices is evaluated. The discussion includes 3D metamaterials, such as gyroidal and hyperbolic arrangements, as well as 2D metasurfaces. Based on recent developments in exploring these emerging structural and material configurations, the review further highlights unexplored opportunities offered by BCP self-assembly for novel metamaterials and metasurface devices

Too Young for the Death Penalty: An Empirical Examination of Community Conscience and the Juvenile Death Penalty from the Perspective of Capital Jurors

As our analysis of jury decisionmaking in juvenile capital trials was nearing completion, the Missouri Supreme Court declared the juvenile death penalty unconstitutional in Simmons v. Roper. The court held that the execution of persons younger than eighteen years of age at the time of their crime violates the Eighth and Fourteenth Amendments to the United States Constitution. This decision patently rejected the U.S. Supreme Court\u27s ruling in Stanford v. Kentucky, which permitted the execution of sixteen- and seventeen-year-olds. In deciding Simmons, the Missouri Supreme Court applied the U.S. Supreme Court\u27s reasoning in Atkins v. Virginia to the juvenile death penalty. In Atkins, the Supreme Court found that there was a national consensus against the death penalty for the mentally retarded that made their execution constitutionally unacceptable. Similarly, in Simmons, the Missouri Supreme Court found that there was a national consensus against the death penalty for juveniles and ruled that juveniles could no longer be executed as a matter of federal constitutional law. The dissenting judges in this four-to-three decision did not take issue with the substantive findings of the majority, but objected instead to what they regarded as the impropriety of their state supreme court making a federal constitutional ruling that contravened an earlier U.S. Supreme Court decision. The U.S. Supreme Court has granted certiorari for a Fall 2004 review of the Simmons case in which it will have an opportunity to consider new evidence on the constitutionality of the juvenile death penalty--evidence of a kind it has lamented not having in earlier death penalty challenges, including specifically a challenge to the juvenile death penalty\u27s constitutionality. This is evidence regarding real capital jurors\u27 exercise of sentencing discretion in cases where they have actually decided whether defendants, whose crimes were committed when they were juveniles, should live or die. This article presents this newly available evidence from capital jurors in an assessment of the constitutionality of the juvenile death penalty. Drawing upon interviews conducted by the Capital Jury Project with persons who served as capital jurors, we are able to compare jurors who served on cases where the defendant was less than eighteen years of age at the time of the crime with those who served on cases with defendants eighteen years of age and older. We can contrast how capital jurors in these cases assessed the culpability of the defendants and the appropriateness of the death sentence

Fluctuations in the emission polarization and spectrum in single chains of a common conjugated polymer for organic photovoltaics

Measuring the nanoscale organization of conjugated polymer chains used in organic photovoltaic (OPV) blends is vital if one wants to understand the materials. This is made very difficult with high efficiency OPV polymers such as PTB7 that form aggregates, as a lack of periodicity and a high degree of disorder make understanding of the nanoscale organization challenging. Here, single molecule spectroscopy is used to observe single chains and aggregates of PTB7. Using four detectors the photoluminescence intensity, wavelength, polarization, and lifetime are simultaneously monitored. Fast (milliseconds) and slow (seconds) fluctuations are observed over a time window of 30 s in all of these observables from single aggregates and chains as individual chromophores activate and deactivate, leading to dynamical changes in the emission spectrum and dipole orientation. This information can be used to help reconstruct the spatial and spectral organization of disordered aggregates of PTB7, thereby adding valuable new information on how the chains are arranged in space

Increased 30-Day Mortality in Very Old ICU Patients with COVID-19 Compared to Patients with Respiratory Failure without COVID-19

Purpose: The number of patients ≥ 80 years admitted into critical care is increasing. Coronavirus disease 2019 (COVID-19) added another challenge for clinical decisions for both admission and limitation of life-sustaining treatments (LLST). We aimed to compare the characteristics and mortality of very old critically ill patients with or without COVID-19 with a focus on LLST. Methods: Patients 80 years or older with acute respiratory failure were recruited from the VIP2 and COVIP studies. Baseline patient characteristics, interventions in intensive care unit (ICU) and outcomes (30-day survival) were recorded. COVID patients were matched to non-COVID patients based on the following factors: age (± 2 years), Sequential Organ Failure Assessment (SOFA) score (± 2 points), clinical frailty scale (± 1 point), gender and region on a 1:2 ratio. Specific ICU procedures and LLST were compared between the cohorts by means of cumulative incidence curves taking into account the competing risk of discharge and death. Results: 693 COVID patients were compared to 1393 non-COVID patients. COVID patients were younger, less frail, less severely ill with lower SOFA score, but were treated more often with invasive mechanical ventilation (MV) and had a lower 30-day survival. 404 COVID patients could be matched to 666 non-COVID patients. For COVID patients, withholding and withdrawing of LST were more frequent than for non-COVID and the 30-day survival was almost half compared to non-COVID patients. Conclusion: Very old COVID patients have a different trajectory than non-COVID patients. Whether this finding is due to a decision policy with more active treatment limitation or to an inherent higher risk of death due to COVID-19 is unclear.info:eu-repo/semantics/publishedVersio

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe